| scholarly article | Q13442814 |
| P50 | author | Sunghwan Suh | Q42719478 |
| Sun Ok Song | Q57332149 | ||
| Byung-Wan Lee | Q64918588 | ||
| P2093 | author name string | Cheol-Young Park | |
| Inkyung Jung | |||
| Sang-Man Jin | |||
| Jae Hyeon Kim | |||
| Chang Hee Jung | |||
| Jae Hyoung Cho | |||
| Jin-Sun Chang | |||
| Seung Min Kang | |||
| P2860 | cites work | Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study | Q36486802 |
| Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. | Q40669494 | ||
| Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death | Q41970353 | ||
| Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. | Q43254579 | ||
| Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan | Q43748015 | ||
| Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis | Q47613876 | ||
| Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes | Q85642529 | ||
| Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies | Q34324440 | ||
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 | ||
| Pioglitazone and bladder cancer: a population-based study of Taiwanese. | Q35688201 | ||
| The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 | ||
| Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study | Q36013549 | ||
| Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis | Q36247512 | ||
| The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. | Q36365241 | ||
| P433 | issue | 2 | |
| P921 | main subject | bladder cancer | Q504775 |
| P304 | page(s) | 238-242 | |
| P577 | publication date | 2014-01-28 | |
| P1433 | published in | Journal of Korean Medical Science | Q24039955 |
| P1476 | title | Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study | |
| P478 | volume | 29 |
| Q38250719 | Antihyperglycaemic therapies and cancer risk |
| Q92418413 | Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment |
| Q38651175 | Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. |
| Q45073276 | Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes |
| Q55356554 | Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study. |
| Q55079635 | Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. |
| Q38721611 | Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis |
| Q91875408 | Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies |
| Q34676639 | Pioglitazone use and risk of bladder cancer: population based cohort study |
| Q55406042 | Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis. |
| Q41107308 | Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes |
| Q30250347 | The current role of thiazolidinediones in diabetes management |
| Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
| Q26750845 | Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs |
Search more.